Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

NOAH study confirmed that trastuzumab combined with chemotherapy can significantly improve PCR compared with chemotherapy alone, and established the status of trastuzumab as a new adjuvant targeted therapy. The emergence of CDK4/6 inhibitors has brought hope to breast cancer patients resistant to endocrine therapy. studies have shown that pyrotinib maleate combined with CDK4/6 inhibitor can significantly inhibit the proliferation of HER2 positive breast cancer cell lines, reduce the activation of pAKT and pHER3, inhibit cell arrest in G0-G1 phase, and increase cell apoptosis. In the mouse mode

Trial Details

NCT ID
NCT05228951
Phase
PHASE2
Sponsor
Shengjing Hospital
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole
Locations (sample)
  • Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

  • Women aged≥18 years and ≤75 years meeting one of the following conditions;
  • Those previously receiving ovariectomy, or aged ≥60 years
  • Those aged \< 60 years who have had 12 consecutive months of amenorrhoea without any pathological or physical causes, and have postmenopausal E2 an…
  • Premenopausal or perimenopausal women who are willing to receive LHRH agonist treatment during the study period

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →